

Gastric Cancer - Pipeline Review, H1 2020

<https://marketpublishers.com/r/G2AB48A7D3DEN.html>

Date: April 2020

Pages: 2197

Price: US\$ 2,500.00 (Single User License)

ID: G2AB48A7D3DEN

Abstracts

Gastric Cancer - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gastric Cancer - Pipeline Review, H1 2020, provides an overview of the Gastric Cancer (Oncology) pipeline landscape.

Gastric cancer, also called stomach cancer, is a malignant tumor arising from the lining of the stomach. Signs and symptoms of gastric cancer include fatigue, stomach pain, vomiting, weight loss that is unintentional, feeling bloated after eating, heartburn and indigestion. Risk factors include smoking, pernicious anemia, stomach polyps, infection with helicobacter pylori and family history of stomach cancer. Treatment includes surgery, chemotherapy and radiation therapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gastric Cancer - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Gastric Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gastric Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gastric Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by

Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 2, 16, 113, 169, 1, 15, 148, 27 and 6 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 11, 9, 1, 8 and 4 molecules, respectively.

Gastric Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Gastric Cancer (Oncology).

The pipeline guide reviews pipeline therapeutics for Gastric Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Gastric Cancer (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Gastric Cancer (Oncology) therapeutics based on

mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Gastric Cancer (Oncology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Gastric Cancer (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Gastric Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Overview

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics
Development

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics
Assessment

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Companies
Involved in Therapeutics Development

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Drug Profiles

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant
Projects

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Discontinued
Products

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Product
Development Milestones

Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Gastric Cancer, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1),
H1 2020

Products under Development by Companies, H1 2020

Products under Development by Universities/Institutes, H1 2020

Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..3), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..4), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..5), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..6), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..7), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..8), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..9), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..3), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..4), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..5), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..6), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..7), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..8), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..9), H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Gastric Cancer - Pipeline by 3SBio Inc, H1 2020

Gastric Cancer - Pipeline by AbbVie Inc, H1 2020

Gastric Cancer - Pipeline by AbClon Inc, H1 2020

Gastric Cancer - Pipeline by AbGenomics International Inc, H1 2020

Gastric Cancer - Pipeline by Abion Inc, H1 2020

Gastric Cancer - Pipeline by ABL Bio Inc, H1 2020

Gastric Cancer - Pipeline by Abpro Corp, H1 2020

Gastric Cancer - Pipeline by Acepodia Biotech Inc, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Gastric Cancer, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

3SBio Inc
AbbVie Inc
AbClon Inc
AbGenomics International Inc
Abion Inc
ABL Bio Inc
Abpro Corp
Acepodia Biotech Inc
Acrotech Biopharma LLC
AD Pharmaceuticals Co Ltd
Adaptimmune Therapeutics Plc
ADC Therapeutics SA
Advenchen Laboratories LLC
Affimed GmbH
AffyImmune Therapeutics Inc
AIMM Therapeutics BV
Akeso Biopharma Inc
Alkermes Plc
Alligator Bioscience AB
Alphamab Oncology
Alteogen Inc

Ambrx Inc
amcure GmbH
Amgen Inc
Andes Biotechnologies
Anew Oncology Inc
Antapodia Therapeutics Inc
Antikor Biopharma Ltd
Apollomics Inc
Apotex Inc
Arbele Ltd
Argonaut Therapeutics Ltd
Arramax Pharmatech Co Ltd
Asana BioSciences LLC
Ascelia Pharma AB
Ascenta Therapeutics Inc
AskAt Inc
Aslan Pharmaceuticals Ltd
Astellas Pharma Inc
AstraZeneca Plc
Atara Biotherapeutics Inc
Aurigene Discovery Technologies Ltd
Aurora BioPharma Inc
Basilea Pharmaceutica Ltd
Bavarian Nordic A/S
Bayer AG
BeiGene Ltd
Beijing BGI-GBI Biotech Co Ltd
Beijing Hanmi Pharmaceutical Co Ltd
Beijing Mabworks Biotech Co Ltd
Beijing Syngentech Co Ltd
Bellicum Pharmaceuticals Inc
Benhealth Biopharmaceutical (Shenzhen) Co Ltd
Betta Pharmaceuticals Co Ltd
Bio-Thera Solutions Ltd
BioEclipse Therapeutics Inc
BioIntegrator Ltd
BioLineRx Ltd
BioMed Valley Discoveries Inc
Biomunex Pharmaceuticals

BioNTech SE
Biosion Inc
Biotechnol Ltd
BJ Bioscience Inc
Bliss Biopharmaceutical (Hangzhou) Co Ltd
Boehringer Ingelheim International GmbH
Bold Therapeutics Inc
Bolt Biotherapeutics Inc
Boston Biomedical Inc
Bristol-Myers Squibb Co
CalyGene Biotechnology Inc
Camel-IDS NV
Cancer Prevention Pharmaceuticals Inc
CARsgen Therapeutics Ltd
CAS-Lamvac Biotech Co Ltd
Catalent Inc
Celldex Therapeutics Inc
Cellestia Biotech AG
Cellid Co Ltd
Cellivery Therapeutics Inc
Cello Therapeutics Inc
Cellular Biomedicine Group Inc
Celon Pharma SA
Cend Therapeutics Inc
Checkmate Pharmaceuticals Inc
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Chipscreen Biosciences Ltd
Chugai Pharmaceutical Co Ltd
Cloaked Therapeutics LLC
CMG Pharmaceutical Co Ltd
Coherent Biopharma
Convalife
CSPC Pharmaceutical Group Ltd
CStone Pharmaceuticals Co Ltd
Cumberland Pharmaceuticals Inc
Curegenix Inc
CureLab Oncology Inc
CureMeta LLC
Cynvec LLC

Cytocom Inc
Cytodyn Inc
CytoMed Therapeutics Pte Ltd
CytomX Therapeutics Inc
Daiichi Sankyo Co Ltd
Delta-Fly Pharma Inc
DiNonA Inc
DM Bio Ltd
Dr. Reddy's Laboratories Ltd
Eddingpharm Inc
eFFECTOR Therapeutics Inc
EirGenix Inc
Eisai Co Ltd
Eli Lilly and Co
EOS Biosciences Inc
ERYTECH Pharma SA
Esperance Pharmaceuticals Inc
Eutilex Co Ltd
Exelixis Inc
EXUMA Biotech Inc
F-star Biotechnology Ltd
F. Hoffmann-La Roche Ltd
Faron Pharmaceuticals Oy
Fate Therapeutics Inc
Five Prime Therapeutics Inc
Frost Biologic Inc
G+FLAS Life Sciences Inc
GEMoaB Monoclonals GmbH
Geneius Biotechnology Inc
Genentech Inc
GeneScience Pharmaceuticals Co Ltd
Genmab AS
Gilead Sciences Inc
GlaxoSmithKline Plc
GLG Pharma SA
GlycoNex Inc
Glycotope GmbH
Good T Cells Inc
Gossamer Bio Inc

Green Cross LabCell Corp
Grid Therapeutics LLC
Guangdong Zhongsheng Pharmaceutical Co Ltd
Hangzhou DAC Biotech Co Ltd
Hanmi Pharmaceuticals Co Ltd
Harbin Gloria Pharmaceuticals Co Ltd
Harbour BioMed
Hengenix Biotech Inc
HengRui YuanZheng Bio-Technology Co Ltd
Hope Biosciences Inc
Horizon Therapeutics PLC
Hummingbird Bioscience Pte Ltd
Hutchison MediPharma Ltd
I-Mab Biopharma Co Ltd
Ichnos Sciences Inc
Igem Therapeutics Ltd
Ildong Pharmaceutical Co Ltd
ImCheck Therapeutics SAS
Immunicum AB
ImmunityBio Inc
Immunocore Ltd
Immunomedics Inc
Immunomet Therapeutics Inc
Immunomic Therapeutics Inc
Imugene Ltd
Incyte Corp
Inhibrx Inc
Innovative Cellular Therapeutics Co Ltd
Innovent Biologics Inc
Inovio Pharmaceuticals Inc
Intra-Immug Pvt Ltd
InxMed Shanghai Co Ltd
Ipsen SA
Jeil Pharmaceutical Co Ltd
JHL Biotech Inc
Jiangsu Atom Bioscience and Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Jiangsu Kanion Pharmaceutical Co Ltd
Jiuzhitang Co Ltd

Johnson & Johnson
Jounce Therapeutics Inc
JW Pharmaceutical Corp
Karyopharm Therapeutics Inc
KLUS Pharma Inc
Komipharm International Co Ltd
Konruns Pharmaceutical Co Ltd
Kringle Pharma Inc
Kupffer Biotherapeutics Inc
Kymab Ltd
Kyowa Kirin Co Ltd
LATITUDE Pharmaceuticals Inc
LegoChem Biosciences Inc
Lepu Medical Technology (Beijing) Co Ltd
Leukocare AG
Luye Pharma Group Ltd
Mabpharm Ltd
MacroGenics Inc
MaxiVAX SA
MBQ Pharma Inc
MedAbome Inc
Meditope Biosciences Inc
MedPacto Inc
Merck & Co Inc
Merck KGaA
Mereo Biopharma Group Plc
Merus NV
Metagone Biotech Inc
Metis Precision Medicine
Millennium Pharmaceuticals Inc
Mitsubishi Tanabe Pharma Corp
Moderna Inc
Molecular Partners AG
Molecular Templates Inc
Moleculin Biotech LLC
Multitude therapeutics Inc
Mustang Bio Inc
Mycenax Biotech Inc
Nanjing Iaso Biotherapeutics Co Ltd

Nanjing Legend Biotech Co Ltd
Nanjing Sanhome Pharmaceutical Co Ltd
Nanjing Tianyi Bioscience Co Ltd
NanoCarrier Co Ltd
NeuClone Pty Ltd
NewBio Therapeutics Inc
NGM Biopharmaceuticals Inc
Nouscom AG
Novartis AG
Novonco Pharmaceuticals Inc
OBI Pharma Inc
Ocellaris Pharma Inc
Ona Therapeutics SL
Oncolmmune Inc
Oncologie Inc
Oncolys BioPharma Inc
OncoSynergy Inc
OncoTherapy Science Inc
Ono Pharmaceutical Co Ltd
Onxeo SA
Opsona Therapeutics Ltd
Orano Med LLC
Oxford BioTherapeutics Ltd
Patrys Ltd
Pepton Inc
PersonGen Biomedicine Suzhou Co Ltd
Pfizer Inc
Phanes Therapeutics Inc
Pharma Mar SA
Pharmapraxis
Phosplatin Therapeutics LLC
Pieris Pharmaceuticals Inc
Plus Therapeutics Inc
PNB Vesper Life Science Pvt Ltd
Prescient Therapeutics Ltd
Prestige BioPharma Pte Ltd
ProLynx LLC
Protheragen Inc
Puma Biotechnology Inc

QED Therapeutics Inc
Qilu Puget Sound Biotherapeutics Corp
Rakuten Medical Inc
RAPT Therapeutics Inc
RaQualia Pharma Inc
Redx Pharma Plc
RemeGen Ltd
Rhizen Pharmaceuticals SA
Richter Gedeon Nyrt
RUS Pharmtech
Samumed LLC
Samyang Holdings Corp
Sanofi
Scancell Holdings Plc
Seattle Genetics Inc
SELLAS Life Sciences Group Inc
Shanghai Biomed-Union Biotechnology Co Ltd
Shanghai Bioray Laboratory Inc
Shanghai GeneChem Co Ltd
Shanghai Haihe Biopharma Co Ltd
Shanghai Henlius Biotech Inc
Shanghai Junshi Bioscience Co Ltd
Shanghai Keqi Pharmaceutical Technology Co Ltd
Shanghai Miracogen Inc
Shanghai Pharmaceutical Group Co Ltd
Shaperon Inc
Shenyang Dongxing Pharmaceutical Co Ltd
Shenzhen BinDeBio Ltd
Shenzhen Fapon Biopharma Inc
Shenzhen Hornetcorn Bio-technology Company Ltd
Shenzhen NeoCura Biotechnology Corp
Shionogi & Co Ltd
Sichuan Kelun Pharmaceutical Co Ltd
Sillajen Biotherapeutics
Sincere Pharmaceutical Group
Sino Biopharmaceutical Ltd
Sinocelltech Ltd
SN BioScience
Sorrento Therapeutics Inc

Sotio AS
Spring Bank Pharmaceuticals Inc
Stcube Inc
Stemirna Therapeutics Inc
StemMed Ltd
Suntec Medical (Taiwan) Inc
Supratek Pharma Inc
Suzhou Sinovent Pharmaceuticals Co Ltd
SynCore Biotechnology Co Ltd
Synthon Holdings BV
T-Cure Bioscience Inc
Taiho Oncology Inc
Taiho Pharmaceutical Co Ltd
Takeda Pharmaceutical Co Ltd
Takis Srl
Tarveda Therapeutics Inc
Tasly Pharmaceutical Group Co Ltd
Tempest Therapeutics Inc
Tessa Therapeutics Pte Ltd
Themis Bioscience GmbH
Tonix Pharmaceuticals Holding Corp
Toray Industries Inc
TOT Biopharm Co Ltd
Treos Bio Ltd
Trio Medicines Ltd
Triumvira Immunologics Inc
Turning Point Therapeutics Inc
Turnstone Biologics Inc
Tvardi Therapeutics Inc
Tyg Oncology Ltd
Ube Industries Ltd
United BioPharma Inc
Vaxon Biotech
Vedanta Biosciences Inc
Venus Remedies Ltd
Viracta Therapeutics Inc
Viral Gene Inc
Well Marker Bio Co Ltd
Wellmarker Bio Co Ltd

Wuhan Binhui Biotechnology Co Ltd
Wuhan YZY Biopharma Co Ltd
Xcovery Holding Co LLC
Xencor Inc
Xiangxue Life Sciences
XuanZhu Pharma Co Ltd
Zai Lab Ltd
Zhejiang Hisun Pharmaceutical Co Ltd
Zhejiang Jianfeng Group Company Ltd
Zhengda Tianqing Kangfang Shanghai Biomedical Technology Co Ltd
Zymeworks Inc

I would like to order

Product name: Gastric Cancer - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/G2AB48A7D3DEN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G2AB48A7D3DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970